$49.3 Bn GLP-1 Markets 2024-2035 with Boehringer Ingelheim, Eli Lilly, Novo Nordisk Dominating
October 01, 2024 04:35 ET
|
Research and Markets
Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "GLP-1 Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type...
Diabetes Drugs Global Strategic Business Report 2024: Market to Surpass $205 Billion by 2030 - Development of GLP-1 Receptor Agonists Expands Treatment Options
September 27, 2024 09:19 ET
|
Research and Markets
Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Diabetes Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Diabetes Drugs...
Global GLP-1 Analogues Market Report 2024-2032: Market Expansion Driven by Innovation and Efficacy in Diabetes and Obesity Treatment - Single Dose and Zepbound Drive Market Domination
August 30, 2024 04:55 ET
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose,...
Obesity Pipeline Research 2024: Insights About 80+ Companies and 100+ Pipeline Drugs - Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type
June 26, 2024 09:29 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Obesity - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Obesity - Pipeline Insight, 2024" report...
Anti-obesity Medication Market Analysis 2024-2034 by Product, Mechanism of Action, Distribution Channel and Region - Global Industry Projected to Register 31.71% CAGR, Reaching $137.4 Billion by 2034
June 26, 2024 06:55 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Medication Market" report has been added to ResearchAndMarkets.com's offering.The global anti-obesity medication market accounted...
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
June 13, 2024 06:38 ET
|
ADALVO LIMITED
Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.
Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Analysis 2024 - The Use of GLP-1R Agonists is Expected to Quadruple in the Next 10 Years, at a CAGR of 14.9%
June 04, 2024 04:17 ET
|
Research and Markets
Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven-Market Drug Forecast and Market Analysis" report has been...
Global Anti-obesity Medication Market Trends Analysis Report 2024-2030: Social Media Influences and Strategic Partnerships, Mergers, Acquisitions, and Collaborations Shaping the Landscape
April 11, 2024 11:14 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Medication Market Size, Share & Trends Analysis Report" report has been added to ResearchAndMarkets.com's offering.The global...
GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI
June 13, 2023 17:30 ET
|
Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...
Peptide-based Metabolic Disorders Therapeutics Market to Surpass US$ 77.9 billion by 2033; As Governments Engage in Supportive Initiatives to Spur Healthcare Sector
March 01, 2023 11:00 ET
|
FACT.MR
Rockville, March 01, 2023 (GLOBE NEWSWIRE) -- The peptide-based metabolic disorder therapeutics market analysis offered by Fact.MR highlights key growth-shaping factors inducing demand in the...